These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15102541)

  • 1. Genetic variability in CYP3A5 and its possible consequences.
    Xie HG; Wood AJ; Kim RB; Stein CM; Wilkinson GR
    Pharmacogenomics; 2004 Apr; 5(3):243-72. PubMed ID: 15102541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic contribution to variable human CYP3A-mediated metabolism.
    Lamba JK; Lin YS; Schuetz EG; Thummel KE
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.
    Krishnakumar D; Gurusamy U; Dhandapani K; Surendiran A; Baghel R; Kukreti R; Gangadhar R; Prayaga U; Manjunath S; Adithan C
    Fundam Clin Pharmacol; 2012 Apr; 26(2):295-306. PubMed ID: 21265876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotyping human CYP2A6 variants.
    Goodz SD; Tyndale RF
    Methods Enzymol; 2002; 357():59-69. PubMed ID: 12424898
    [No Abstract]   [Full Text] [Related]  

  • 5. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
    Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
    Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
    Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
    Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques.
    Uno Y; Matsushita A; Osada N; Uehara S; Kohara S; Nagata R; Fukuzaki K; Utoh M; Murayama N; Yamazaki H
    Drug Metab Dispos; 2010 Feb; 38(2):209-14. PubMed ID: 19910514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.
    Mwenifumbo JC; Tyndale RF
    Pharmacogenomics; 2007 Oct; 8(10):1385-402. PubMed ID: 17979512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
    Lamba JK; Lin YS; Thummel K; Daly A; Watkins PB; Strom S; Zhang J; Schuetz EG
    Pharmacogenetics; 2002 Mar; 12(2):121-32. PubMed ID: 11875366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of cytochrome P450 2A6 polymorphism in nicotine metabolism and tobacco-dependent behaviour].
    Xia XY; Peng RX
    Yao Xue Xue Bao; 2004 Sep; 39(9):758-63. PubMed ID: 15606031
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism.
    Oscarson M
    Drug Metab Dispos; 2001 Feb; 29(2):91-5. PubMed ID: 11159795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Researches on the polymorphism of cytochrome P450 2A6].
    Tong Z; ZhuGe J; Yu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Oct; 19(5):424-7. PubMed ID: 12362322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic CYP2A6 and its clinical and toxicological significance.
    Rautio A
    Pharmacogenomics J; 2003; 3(1):5-7. PubMed ID: 12629576
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic polymorphism of CYP2A6 in the German population.
    Bourian M; Gullstén H; Legrum W
    Toxicology; 2000 Apr; 144(1-3):129-37. PubMed ID: 10781880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2A6 polymorphism reveals differences in Japan and the existence of a specific variant in Ovambo and Turk populations.
    Takeshita H; Hieda Y; Fujihara J; Xue Y; Nakagami N; Takayama K; Imamura S; Kataoka K
    Hum Biol; 2006 Apr; 78(2):235-42. PubMed ID: 17036930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
    Yoshida R; Nakajima M; Nishimura K; Tokudome S; Kwon JT; Yokoi T
    Clin Pharmacol Ther; 2003 Jul; 74(1):69-76. PubMed ID: 12844137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.
    Nakajima M
    Curr Opin Mol Ther; 2007 Dec; 9(6):538-44. PubMed ID: 18041664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
    Zand N; Tajik N; Moghaddam AS; Milanian I
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
    Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
    J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cytochrome P450 isozymes in metabolism and health effects of gasoline ethers.
    Hong JY; Wang YY; Mohr SN; Bondoc FY; Deng C
    Res Rep Health Eff Inst; 2001 May; (102):7-27; discussion 95-109. PubMed ID: 11504148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.